Literature DB >> 18781404

Aspirin in asymptomatic patients with a confirmed positivity of antiphospholipid antibodies.

Stefania Basili, Francesco Violi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18781404     DOI： 10.1007/s11739-008-0193-4

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  17 in total

1.  Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.

Authors:  Emily Somers; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  Soluble CD154 plasma levels in patients with systemic lupus erythematosus: modulation by antiphospholipid antibodies.

Authors:  Domenico Ferro; Pasquale Pignatelli; Lorenzo Loffredo; Fabrizio Conti; Guido Valesini; Armando D'Angelo; Francesco Violi
Journal:  Arthritis Rheum       Date:  2004-05

3.  Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Authors:  Jeffrey S Berger; Maria C Roncaglioni; Fausto Avanzini; Ierta Pangrazzi; Gianni Tognoni; David L Brown
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

4.  Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases).

Authors:  Maria Gerosa; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Intern Emerg Med       Date:  2008-07-01       Impact factor: 3.397

5.  Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.

Authors:  D Ferro; S Basili; S Roccaforte; M Di Franco; F Cipollone; G Ciabattoni; G Davì
Journal:  Arthritis Rheum       Date:  1999-12

6.  A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study).

Authors:  I A Naess; S C Christiansen; S C Cannegieter; F R Rosendaal; J Hammerstroem
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

Review 7.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.

Authors:  G Finazzi; V Brancaccio; M Moia; N Ciaverella; M G Mazzucconi; P C Schinco; M Ruggeri; E M Pogliani; G Gamba; E Rossi; F Baudo; C Manotti; A D'Angelo; G Palareti; V De Stefano; M Berrettini; T Barbui
Journal:  Am J Med       Date:  1996-05       Impact factor: 4.965

9.  Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.

Authors:  José A Girón-González; Enrique García del Río; Carmen Rodríguez; Javier Rodríguez-Martorell; Ascensión Serrano
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

10.  Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.

Authors:  T Hereng; M Lambert; E Hachulla; M Samor; S Dubucquoi; C Caron; D Launay; S Morell-Dubois; V Queyrel; P-Y Hatron
Journal:  Lupus       Date:  2008-01       Impact factor: 2.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.